Condition: Advanced Cancer · Metastatic Cancer · Sponsor: invoX Pharma Limited
This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.
This description comes directly from the study's public registry record.
invoX Clinical Trials · +44 2038 820886 · info@invoxpharma.com
Always discuss trial participation with your own doctor first.
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Recruiting |
| One Clinical Research Perth | Perth, Western Australia, Australia | Recruiting |
| Arensia Exploratory Medicine, LLC | Tbilisi, Georgia | Recruiting |
| SLK Kliniken Heilbronn GmbH | Heilbronn, Baden-Wurttemberg, Germany | Recruiting |
| Radboud Universitair Medisch Centrum | Nijmegen, Gelderland, Netherlands | Recruiting |
| Centrum Medyczne Poznan - PRATIA - PPDS | Poznan, Greater Poland Voivodeship, Poland | Recruiting |
| MCM Krakow - PRATIA - PPDS | Krakow, Poland | Recruiting |
| Prof. Dr. Alexandru Trestioreanu Oncologic Institute | Bucharest, Romania | Recruiting |
| Prof Dr I Chiricuta Institute of Oncology | Cluj-Napoca, Romania | Recruiting |
| Clinica Universidad Navarra | Pamplona, Navarre, Spain | Recruiting |
| NEXT - Hospital Quironsalud Barcelona | Barcelona, Spain | Recruiting |
| Hospital Universitari Vall D'Hebron | Barcelona, Spain | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04740424